An employee of the pharmaceutical giant AstraZeneca is accused of insider trading after allegedly buying stock in a company shortly before it was acquired by his employer. The U.S. Securities and Exchange Commission filed a complaint Wednesday in Maryland U.S. District Court against Weiguo Zhai, 56, of Potomac, who worked as a senior director for research and development at AstraZeneca from July 2020 until May 2024.